文献速递先天性心脏病外科

马西替坦在Fontan术后患者中的疗效与安全性:RUBATO Ⅲ期试验

Efficacy and safety of macitentan in Fontan-palliated patients: 52-week randomized, placebo-controlled RUBATO Phase 3 trial and open-label extension.
PubMed 文献 · J Thorac Cardiovasc Surg · 2024-08-29

RUBATO-DB为52周前瞻性多中心双盲随机安慰剂对照平行组研究,评估马西替坦在Fontan术后成人和青少年患者中的疗效与安全性,并设开放标签延长期RUBATO-OL。137例患者随机接受马西替坦10 mg(n=68)或安慰剂(n=69);第16周峰值耗氧量变化主要终点未达到,马西替坦未改善运动能力,长期治疗总体耐受良好。

要点

  • RUBATO-DB主要终点未达到:马西替坦未改善Fontan术后患者运动能力。
  • 第16周峰值耗氧量变化马西替坦组-0.16±2.86 vs 安慰剂组-0.67±2.66 mL/kg/minute,P=.19。
  • RUBATO-OL因RUBATO-DB未达主要或次要终点而提前终止。

核心结论

  • RUBATO-DB主要终点未达到,马西替坦与安慰剂相比未改善Fontan术后患者的运动能力。
  • 马西替坦长期治疗总体耐受良好。

研究设计与样本

  • 52周前瞻性、多中心、双盲、随机、安慰剂对照、平行组研究(RUBATO-DB)及开放标签延长期试验(RUBATO-OL)。
  • 纳入12岁及以上、纽约心功能Ⅱ或Ⅲ级、筛选前1年以上行全腔静脉肺动脉连接术且无Fontan失败/临床恶化征象的患者。
  • RUBATO-DB共随机137例,马西替坦10 mg组n=68,安慰剂组n=69;92.7%完成52周双盲治疗。

主要发现

  • 第16周峰值耗氧量相对基线变化:马西替坦组-0.16±2.86 vs 安慰剂组-0.67±2.66 mL/kg/minute(中位无偏治疗差异估计值0.62 mL/kg/minute,99%重复CI -0.62至1.85;P=.19)。
  • 两项次要终点均未观察到治疗效应。
  • RUBATO-DB期间马西替坦组最常见不良事件为头痛、鼻咽炎和发热;RUBATO-DB与RUBATO-OL合并最常见不良事件为COVID-19、头痛和乏力。
  • RUBATO-OL因RUBATO-DB未达到主要或次要终点而提前终止。

关键数值与推荐

  • 主要疗效终点:第16周峰值耗氧量相对基线变化。
  • 次要终点:52周内峰值耗氧量相对基线变化,以及第16周加速度计测得的每日体力活动平均计数/分钟相对基线变化。
  • 马西替坦剂量10 mg。

临床怎么用

  • 本试验结果不支持马西替坦用于改善Fontan术后患者的运动能力。
  • 马西替坦在长期治疗中总体耐受良好,不良事件以头痛、鼻咽炎、发热及COVID-19、乏力为主。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The efficacy and safety of macitentan, an endothelin receptor antagonist, were assessed in a 52-week, prospective, multicenter, double-blind, randomized, placebo-controlled, parallel-group study assessing the efficacy and safety of macitentan in Fontan-palliated adult and adolescent patients (RUBATO-DB) and an open-label extension trial (RUBATO-OL). METHODS: Patients aged 12 years and older with New York Heart Association functional class II or III underwent total cavopulmonary connection more than 1 year before screening and showed no signs of Fontan failure/clinical deterioration. In RUBATO-DB, the primary efficacy end point was change in peak oxygen consumption from baseline to week 16; secondary end points were change from baseline over 52 weeks in peak oxygen consumption and change in mean count/minute of daily physical activity via accelerometer from baseline to week 16. Safety was assessed throughout both studies. RESULTS: In RUBATO-DB, 137 patients were randomized to macitentan 10 mg (n = 68) or placebo (n = 69); 92.7% completed 52-week double-blind treatment. At week 16, mean ± SD change in peak oxygen consumption was -0.16 ± 2.86 versus -0.67 ± 2.66 mL/kg/minute with macitentan versus placebo (median unbiased treatment difference estimate, 0.62 mL/kg/minute [99% repeated CI, -0.62 to 1.85]; P = .19). No treatment effect was observed in either of the secondary end points. During RUBATO-DB, most common adverse events with macitentan were headache, nasopharyngitis, and pyrexia. Across RUBATO-DB and RUBATO-OL, most common adverse events were COVID-19, headache, and fatigue. RUBATO-OL was prematurely discontinued because RUBATO-DB did not meet its primary or secondary end point. CONCLUSIONS: The primary end point of RUBATO-DB was not met; macitentan did not improve exercise capacity versus placebo in patients with Fontan palliation. Macitentan was generally well tolerated over long-term treatment.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Clift P, Berger F, Sondergaard L, et al. Efficacy and safety of macitentan in Fontan-palliated patients: 52-week randomized, placebo-controlled RUBATO Phase 3 trial and open-label extension. J Thorac Cardiovasc Surg. 2024. PMID: 39216715. doi:10.1016/j.jtcvs.2024.08.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。